LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Open

3.51 2.33

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.27

Max

3.51

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.5M -4.5M
Gewinnspanne	-2,954
Angestellte	21

Dividenden
By Dow Jones
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.3M 27M
Vorheriger Eröffnungskurs	1.18
Vorheriger Schlusskurs	3.51

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Juni 2026, 20:30 UTC

Ergebnisse

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2. Juni 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2. Juni 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Juni 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2. Juni 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2. Juni 2026, 23:01 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2. Juni 2026, 23:01 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2. Juni 2026, 23:00 UTC

Akquisitionen, Fusionen, Übernahmen

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2. Juni 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2. Juni 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2. Juni 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. Juni 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2. Juni 2026, 21:00 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2. Juni 2026, 20:46 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:38 UTC

Ergebnisse

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2. Juni 2026, 20:21 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:12 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Product Rev $594M

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Adj EPS 85c >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Loss $177M >PANW

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

Neutral

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.